Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

Completed · Phase 2

Conditions studied: Marginal Zone Lymphoma, MZL

In brief

This is a single arm study to evaluate the efficacy, safety and tolerability of zanubrutinib (BGB-3111) in participants with relapsed/refractory marginal zone lymphoma (R/R MZL).

Key facts

Study ID
NCT03846427
Run by
BeiGene
People needed
68
Starts
2019-02-19
Expected to finish
2022-05-04
Last updated by the study team
2024-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.